Results 91 to 100 of about 46,982 (194)

Prostate Cancer Development, Progression, and Therapy

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin, Zicheng Xiao, Zexian Ding, Wei Li, Ruijiang Zeng, Yujun Shuai, Weimin Ci, Dan Xia, Xu Zhang, Haojie Huang   +9 more
wiley   +1 more source

Advancing Glioblastoma Treatment: The Emerging Role of CAR-T Cell Therapy

Journal of Radiation and Cancer Research
Glioblastoma (GBM) remains one of the most aggressive and lethal brain tumors, with standard treatment – comprising maximal surgical resection followed by radiotherapy and temozolomide – offering only modest improvements in survival.
Jahnabi Das, Tapashi Das, Abhinandan Das, Jyotiman Nath, Yanpothung Yanthan, Kaushik Kataki   +5 more
doaj   +1 more source

Claudin‐6 Protein Expression in Atypical Teratoid/Rhabdoid Tumors Is Strongly Enriched in the Molecular Subgroup AT/RT‐TYR

Pediatric Blood &Cancer, Volume 73, Issue 8, August 2026.
ABSTRACT Claudin‐6 has emerged as a promising immunotherapeutic target, yet protein‐level data in atypical teratoid/rhabdoid tumors (AT/RTs) have been inconsistent. We analyzed 36 well‐characterized AT/RT samples and found membranous claudin‐6 protein expression in 58% of cases, with striking enrichment in the molecular subgroup AT/RT‐TYR (100%) and ...
Victoria E. Fincke, Christian Thomas, Michael C. Frühwald, Pascal D. Johann, Martin Hasselblatt   +4 more
wiley   +1 more source

FUCA2 Sustains AKT Signaling and Suppresses Senescence by Antagonizing FUT3‐Mediated ErbB3 Fucosylation in Lung Adenocarcinoma

Advanced Science, Volume 13, Issue 44, 7 August 2026.
ABSTRACT While targeted therapies have improved outcomes in lung adenocarcinoma (LUAD), many patients still lack targetable mutations. Here, we identified alpha‐L‐fucosidase 2 (FUCA2) as a crucial driver of LUAD by preventing cellular senescence. Mechanistically, through the restriction of fucosyltransferase 3 (FUT3)‐mediated α‐1,3‐fucosylation of ...
Lu Chen, Jintao Guo, Fei Li, Mingjie Gao, Runyang Li, Zhaozhang Huang, Yaolin Zheng, Chunyi Gao, Jihuan Hou, Qiang Yu, Bowen Zheng, Xuemei Chen, Wenqing Zhang, Xiaoting Hong, Yali Zheng, Daxuan Wang, Qiyuan Li, Tianhui Hu, Yan‐yan Zhan   +18 more
wiley   +1 more source

Therapeutic Applications of Stimuli‐Based Release and Engineering of Extracellular Vesicles

Advanced NanoBiomed Research, Volume 6, Issue 8, August 2026.
This review summarizes the effects of endogenous and exogenous stimuli, their effects on the natural release of extracellular vesicles, as well as their uptake and release. It also gives an overview of stimuli‐responsive EVs and their therapeutic applications. Extracellular vesicles (EVs), nano‐ to microsized lipid bilayer membrane‐bound particles, are
Gloria Kemunto, Kristen Dellinger
wiley   +1 more source

Preclinical evaluation of antitumor activity and toxicity of TROP2-specific CAR-T cells for treatment of triple-negative breast cancer

Journal for ImmunoTherapy of Cancer
Background Triple-negative breast cancer (TNBC) represents a subtype of breast cancer with poorest prognosis due to limited effective targeted therapies.
Lu Zhang, Li Yan, Yang Xu, Xiaojia Wang, Fei Wu, Shuqun Zhang, Shiyu Sun, Huizi Wu, Yongchen Chen, Ziwei Liang, Zuomin Nian, Wanni Xu, Wenzhou Wang, Yiwei Jia, Xingcong Ma   +14 more
doaj   +1 more source

Applications of Artificial Intelligence in Cancer Diagnosis and Treatment

Cancer Medicine, Volume 15, Issue 8, August 2026.
This review explores how AI and multimodal data fusion transform oncology through enhanced screening, precision diagnosis, and personalized therapy. By dissecting core challenges—including data bias and explainability—it provides a strategic framework for the digital transformation and ethical implementation of AI in clinical cancer care.
Yifeng Xie, Zixuan Wang, Zhiwen Zeng, Tongyao Xin, Shaofei Yuan, Feiwei Qin, Zhonglin Chen   +6 more
wiley   +1 more source

Vobramitamab duocarmazine, an anti–B7‐H3 antibody–drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion

Cancer, Volume 132, Issue 15, 1 August 2026.
Abstract Background Vobramitamab duocarmazine is an investigational antibody–drug conjugate (ADC) targeting B7 homolog 3 (B7‐H3) with a cytotoxic duocarmycin‐based DNA‐alkylating payload. This study evaluated its safety and antitumor activity in advanced solid tumors.
Eugene Shenderov, Manish R. Sharma, Elena Garralda, John Powderly, Iwona Ługowska, Alexander Spira, Marc Cucurull Salamero, Sekwon Jang, Rasha Cosman, John Shen, Wen Xu, Piotr J. Wysocki, Rodryg Ramlau, Emmanuel S. Antonarakis, Andrew J. Weickhardt, Jakub Żołnierek, Emiliano Calvo, Enxu Zhao, Chet Bohac, Ashley Ward, Girish Mallesara   +20 more
wiley   +1 more source

The evolving landscape of the Warburg effect in gastric cancer: From molecular mechanisms to targeted therapy

Clinical and Translational Medicine, Volume 16, Issue 8, August 2026.
Hypoxia, oncogenic signaling, transcriptional and epigenetic remodeling, and H. pylori–microbiota interactions drive the Warburg effect in gastric cancer. Enhanced glycolysis and lactate export support biosynthesis, remodel the tumor microenvironment, promote stromal activation and immune suppression, and reveal actionable biomarkers and therapeutic ...
Guanmo Liu, Pan Li, Zizhuo Li, Jie Li, Chenggang Zhang, Yihua Wang, Weiming Kang, Xin Ye   +7 more
wiley   +1 more source

The Role of Precision Medicine in Neuroblastoma: Targeted Therapies and Personalized Approaches—A Narrative Review

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims Neuroblastoma is the most common extracranial solid tumor and contributes the most to pediatric oncology deaths worldwide. Its clinical manifestations are heterogeneous, including relapses, and the prognosis remains poor, especially for high‐risk patients.
Mosammat Jannatul Mawa, Mohammad Shahangir Biswas, Maksudul Haque, Munna Kumar Podder   +3 more
wiley   +1 more source